NEW ORLEANS In a subgroup analysis of the ASCENT COPD trial treatment with the long acting antimuscarinic bronchodilator aclidinium bromide reduced the risk for new exacerbations compared with placebo in patients with moderate to very severe COPD and high cardiovascular risk regardless of prior exacerbations Further the data highlight equivalent safety in terms of major adverse CV events and mortality Robert Wise MD FCCP professor of medicine at Johns Hopkins University School of Medicine told Healio Pulmonology This activity is supported by an educational grant from Genentech Inc Cardiometabolic Health Congress Already registered Log in now Tell us what you think about Healio com Get the latest news and education delivered to your inbox  Healio All Rights Reserved Tell us what you think about Healio com Get the latest news and education delivered to your inbox  Healio All Rights Reserved